CN114989298A - 针对vegf的d-肽化合物 - Google Patents

针对vegf的d-肽化合物 Download PDF

Info

Publication number
CN114989298A
CN114989298A CN202210386453.7A CN202210386453A CN114989298A CN 114989298 A CN114989298 A CN 114989298A CN 202210386453 A CN202210386453 A CN 202210386453A CN 114989298 A CN114989298 A CN 114989298A
Authority
CN
China
Prior art keywords
vegf
peptide
compound
helix
cases
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202210386453.7A
Other languages
English (en)
Chinese (zh)
Inventor
P·马里纳克
K·兰德格拉夫
D·阿尔特-里彻
M·C·尤帕拉帕蒂
S·西德胡
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Toronto
Reflection Pharmaceutical Co ltd
Original Assignee
University of Toronto
Reflection Pharmaceutical Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Toronto, Reflection Pharmaceutical Co ltd filed Critical University of Toronto
Publication of CN114989298A publication Critical patent/CN114989298A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/001—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof by chemical synthesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
    • A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
    • A61K49/0041—Xanthene dyes, used in vivo, e.g. administered to a mice, e.g. rhodamines, rose Bengal
    • A61K49/0043—Fluorescein, used in vivo
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
    • A61K49/0056—Peptides, proteins, polyamino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
    • A61K49/0058—Antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Biomedical Technology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Cell Biology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Peptides Or Proteins (AREA)
CN202210386453.7A 2019-03-22 2020-03-20 针对vegf的d-肽化合物 Pending CN114989298A (zh)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US201962822241P 2019-03-22 2019-03-22
US62/822,241 2019-03-22
US201962865469P 2019-06-24 2019-06-24
US62/865,469 2019-06-24
PCT/US2020/024053 WO2020198074A1 (en) 2019-03-22 2020-03-20 D-peptidic compounds for vegf
CN202080038052.1A CN114174334A (zh) 2019-03-22 2020-03-20 针对vegf的d-肽化合物

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN202080038052.1A Division CN114174334A (zh) 2019-03-22 2020-03-20 针对vegf的d-肽化合物

Publications (1)

Publication Number Publication Date
CN114989298A true CN114989298A (zh) 2022-09-02

Family

ID=70285984

Family Applications (3)

Application Number Title Priority Date Filing Date
CN202210386453.7A Pending CN114989298A (zh) 2019-03-22 2020-03-20 针对vegf的d-肽化合物
CN202080038052.1A Pending CN114174334A (zh) 2019-03-22 2020-03-20 针对vegf的d-肽化合物
CN202411356232.0A Pending CN119930814A (zh) 2019-03-22 2020-03-20 针对vegf的d-肽化合物

Family Applications After (2)

Application Number Title Priority Date Filing Date
CN202080038052.1A Pending CN114174334A (zh) 2019-03-22 2020-03-20 针对vegf的d-肽化合物
CN202411356232.0A Pending CN119930814A (zh) 2019-03-22 2020-03-20 针对vegf的d-肽化合物

Country Status (7)

Country Link
US (1) US20210061861A1 (enExample)
EP (1) EP3941580A1 (enExample)
JP (3) JP2022521353A (enExample)
KR (2) KR20220044612A (enExample)
CN (3) CN114989298A (enExample)
TW (3) TW202523683A (enExample)
WO (1) WO2020198074A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2024524613A (ja) 2021-07-14 2024-07-05 ライシア セラピューティクス， インコーポレイテッド Ｍ６ｐｒ細胞表面受容体結合化合物及びコンジュゲート
KR102662922B1 (ko) * 2022-05-31 2024-05-03 주식회사 세네릭스 신규의 d-아미노산 유도체 및 이를 포함하는 약학 조성물
CN120835794A (zh) 2023-01-18 2025-10-24 利西亚治疗公司 M6pr结合化合物和缀合物

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010014830A2 (en) * 2008-07-30 2010-02-04 Cosmix Therapeutics Llc Peptide therapeutics that bind vegf and methods of use thereof
US20120129715A1 (en) * 2010-11-12 2012-05-24 Sidhu Sachdev S Gb1 peptidic libraries and methods of screening the same
WO2014071234A1 (en) * 2012-11-02 2014-05-08 The Governing Council Of The University Of Toronto Gb1 peptidic compounds and methods for making and using the same

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE240394T1 (de) 1992-10-23 2003-05-15 Immunex Corp Methoden zur herstellung löslicher, oligomerer proteine
SE9400088D0 (sv) 1994-01-14 1994-01-14 Kabi Pharmacia Ab Bacterial receptor structures
US6740734B1 (en) 1994-01-14 2004-05-25 Biovitrum Ab Bacterial receptor structures
US6811779B2 (en) 1994-02-10 2004-11-02 Imclone Systems Incorporated Methods for reducing tumor growth with VEGF receptor antibody combined with radiation and chemotherapy
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
GB9708265D0 (en) 1997-04-24 1997-06-18 Nycomed Imaging As Contrast agents
US6660843B1 (en) 1998-10-23 2003-12-09 Amgen Inc. Modified peptides as therapeutic agents
US6887470B1 (en) 1999-09-10 2005-05-03 Conjuchem, Inc. Protection of endogenous therapeutic peptides from peptidase activity through conjugation to blood components
EP1274720A4 (en) 2000-04-12 2004-08-18 Human Genome Sciences Inc FUSION PROTEINS CONTAINING ALBUMIN
US20050054051A1 (en) 2001-04-12 2005-03-10 Human Genome Sciences, Inc. Albumin fusion proteins
EP1587944A4 (en) * 2002-03-01 2007-03-21 Dyax Corp KDR AND VEGF / KDR BINDING PEPTIDES AND THEIR USE FOR DIAGNOSTIC AND THERAPEUTIC PURPOSES
US20030191056A1 (en) 2002-04-04 2003-10-09 Kenneth Walker Use of transthyretin peptide/protein fusions to increase the serum half-life of pharmacologically active peptides/proteins
US8545809B2 (en) 2007-01-11 2013-10-01 Immunomedics, Inc. Methods and compositions for improved 18F labeling of proteins, peptides and other molecules
EP2077272A1 (en) 2007-12-21 2009-07-08 Affibody AB Polypeptide libraries with a predetermined scaffold
HK1218534A1 (zh) * 2013-03-14 2017-02-24 多伦多大学管理委员会 支架化肽文库以及其制备和筛选方法
KR102497083B1 (ko) 2013-08-28 2023-02-07 애피바디 에이비 돌연변이된 스캐폴드를 갖는 결합 폴리펩티드
WO2015112700A1 (en) * 2014-01-22 2015-07-30 Wisconsin Alumni Research Foundation Alpha/beta-peptide mimics of z-domain peptides
WO2016059068A1 (en) * 2014-10-13 2016-04-21 Affibody Ab Vegfr-2 binding polypeptides
JP2016123342A (ja) * 2014-12-26 2016-07-11 国立研究開発法人産業技術総合研究所 Ｖｅｇｆ結合性ペプチド
BR112017020986A2 (pt) * 2015-04-02 2018-08-14 Molecular Partners Ag. proteínas de ligação recombinantes e seu uso
WO2016208761A1 (ja) * 2015-06-25 2016-12-29 公立大学法人大阪府立大学 薬物複合体

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010014830A2 (en) * 2008-07-30 2010-02-04 Cosmix Therapeutics Llc Peptide therapeutics that bind vegf and methods of use thereof
US20100093624A1 (en) * 2008-07-30 2010-04-15 Cosmix Therapeutics Llc Peptide therapeutics that bind vegf and methods of use thereof
US20120129715A1 (en) * 2010-11-12 2012-05-24 Sidhu Sachdev S Gb1 peptidic libraries and methods of screening the same
WO2012078313A2 (en) * 2010-11-12 2012-06-14 Reflexion Pharmaceuticals, Inc. Gb1 peptidic libraries and compounds, and methods of screening the same
WO2014071234A1 (en) * 2012-11-02 2014-05-08 The Governing Council Of The University Of Toronto Gb1 peptidic compounds and methods for making and using the same

Also Published As

Publication number Publication date
JP2024149556A (ja) 2024-10-18
CN119930814A (zh) 2025-05-06
KR20220029545A (ko) 2022-03-08
EP3941580A1 (en) 2022-01-26
WO2020198074A1 (en) 2020-10-01
CN114174334A (zh) 2022-03-11
TW202523683A (zh) 2025-06-16
TWI820657B (zh) 2023-11-01
TW202241936A (zh) 2022-11-01
JP2022082754A (ja) 2022-06-02
KR20220044612A (ko) 2022-04-08
JP2022521353A (ja) 2022-04-06
US20210061861A1 (en) 2021-03-04
TW202102532A (zh) 2021-01-16

Similar Documents

Publication Publication Date Title
KR102632418B1 (ko) 영상화를 위한 신규 pd-l1 결합 폴리펩티드
KR102397783B1 (ko) Pd-l1 결합 폴리펩티드에 의한 pet 영상화
KR101287280B1 (ko) 태반 성장 인자 매개된 전이 및/또는 혈관신생의 억제
EP3893913A1 (en) Transferrin receptor targeting peptides
JP2024149556A (ja) Ｖｅｇｆのためのｄ－ペプチド性化合物
BR122020010972B1 (pt) polipeptídeo isolado e de fusão, sua composição farmacêutica e multímero
JP2016521688A (ja) 肝細胞増殖因子に結合する設計アンキリン反復タンパク質
JP2008512356A (ja) 治療及び診断用途のための多価構築体の製造方法
KR20150083840A (ko) Her3 결합 폴리펩티드
WO2021222593A2 (en) Pd-l1 binding peptides
US20230051872A1 (en) Multivalent D-Peptidic Compounds for Target Proteins
JP7703541B2 (ja) 血清アルブミン結合性フィブロネクチンｉｉｉ型ドメインおよびその使用
CN111511917B (zh) 肽结合物
WO2014071234A1 (en) Gb1 peptidic compounds and methods for making and using the same
Hackel Alternative protein scaffolds for molecular imaging and therapy
WO2014034922A1 (ja) 血管内皮細胞増殖因子受容体阻害ペプチド
WO2025206033A1 (ja) ｕＰＡＲ結合性ＨＬＨペプチド、ペプチド－薬物複合体および組成物
US20120178682A1 (en) GB1 Peptidic Compounds and Methods for Making and Using the Same
HK40109540A (zh) 反式环辛烯缀合物

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20220902